Search the Newsreel

Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. significantly reduced its stake in Supernus Pharmaceuticals (NASDAQ:SUPN) by 86.2% in the second quarter, selling 457,443 shares and retaining 73,175 shares valued at $3.4 million. Despite this large sale, analyst sentiment for Supernus remains generally positive, with a "Moderate Buy" …

Indivior Pharmaceuticals (INDV) Agrees Merger That Creates New Supernus, Inc.

Indivior Pharmaceuticals (NasdaqGS: INDV) has agreed to merge with Supernus Pharmaceuticals, forming a new entity named Supernus, Inc., with shared leadership. This merger is expected to significantly reshape both companies' corporate governance and operations, especially concerning Indivior's buprenorphine-based treatments. Investors should watch the combined …

Supernus Pharmaceuticals, Inc. (SUPN) Investor Outlook: A 31% Upside Potential Amid Strong Revenue Growth

Supernus Pharmaceuticals, Inc. (SUPN) is highlighted as a prominent player in CNS therapies with a 31.19% projected upside based on analyst targets, despite recent challenges in profitability. The company boasts strong revenue growth of 32.40% and a healthy free cash flow, indicating potential for …

Supernus Pharmaceuticals (SUPN) Stock May Be A Bargain After Merger News

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Supernus Pharmaceuticals has almost doubled investors' money over the past five years, yet the stock still screens as cheap on the broad valuation checks. …

Supernus Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:SUPN)

Supernus Pharmaceuticals, Inc. (SUPN) Stock Forecasts

Argus has lowered its target price for Supernus Pharmaceuticals Inc. (SUPN) to $41.00, while the current stock price is $47.64. Supernus Pharmaceuticals specializes in developing and commercializing treatments for central nervous system diseases. Investors can access the full report with a Yahoo Finance Silver …

Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Increased to Strong-Buy at Zacks Research

Zacks Research has upgraded Supernus Pharmaceuticals (NASDAQ:SUPN) from a "hold" to a "strong-buy" rating. This upgrade comes despite a broader analyst consensus of "Moderate Buy" with a target price of $62.83. The company, which specializes in central nervous system therapies, also saw several institutional …

Supernus Pharmaceuticals, Inc. (SUPN) Indivior Pharmaceuticals, Inc., - M&A Call - Slideshow

This article provides access to a slide deck published by Supernus Pharmaceuticals, Inc. concerning an M&A call related to Indivior Pharmaceuticals, Inc. The content is presented by SA Transcripts, a team responsible for developing and publishing earnings call transcripts on Seeking Alpha.

SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?

Investors with an interest in Medical - Generic Drugs stocks have likely encountered both Supernus Pharmaceuticals (SUPN) and Teva Pharmaceutical Industries Ltd. (TEVA). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find …

Renascor Resources (ASX:RNU) moves into focus as project progress

supernus pharmaceuticals, inc. Positive Earnings Pre-Announcements

Supernus Pharmaceuticals, Inc. announced positive earnings pre-announcements, updating its fiscal year 2026 revenue range from $840-$870 Million to $860-$890 Million. The company has been active in mergers and acquisitions, including a proposed merger with Indivior and an acquisition of Sage Therapeutics, and has seen …

Supernus Pharmaceuticals (SUPN) Jumps On Merger Terms, Is The Stock Still Cheap?

Supernus Pharmaceuticals Inc (SUPN) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth ...

Supernus Pharmaceuticals Inc (SUPN) reported strong revenue growth in Q2 2026, driven by key product sales and advancements in its late-stage pipeline. Despite competitive pressures and increased R&D expenses, the company reaffirmed its full-year financial guidance, projecting net revenue between $640 million and $660 …

What Keeps What Could Renascor Resources (ASX:RNU) on Watch This Reporting Season?

INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook

Indivior Pharmaceuticals INDV has announced a definitive agreement to merge with Supernus Pharmaceuticals SUPN in a tax-free, all-stock merger of equals. The transaction will create a leading central nervous system (CNS)-focused biopharmaceutical company with a diversified portfolio of 11 marketed medicines spanning psychiatry, neurology …

Supernus and Indivior merge to create scaled, CNS-focused entity

Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in an all-stock deal to form a diversified biopharmaceutical company focused on the central nervous system (CNS). The combined entity, which will operate under the name Supernus Inc. and trade on Nasdaq under 'SUPN', expects pro forma …

Supernus Pharmaceuticals (SUPN) Stock Rebounds As Revenue Growth Meets Profit Crunch

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)

Monteverde & Associates PC, a class action firm, has announced an investigation into Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) concerning its proposed sale to Indivior Pharmaceuticals, Inc. The firm is examining whether the deal, where Supernus shareholders would receive 1.5401 common shares of Indivior for …

Indivior and Supernus (SUPN) outline tax-free all-stock CNS merger of equals

Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. announced a definitive agreement to merge in an all-stock, tax-free transaction, creating a U.S. biopharmaceutical company focused on central nervous system (CNS) diseases. The combined entity will be headquartered in Rockville, Maryland, with Supernus CEO Jack A. …

Halper Sadeh LLC is Investigating Whether SUPN, ITGR, BOW are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We …

Supernus Pharmaceuticals Earnings: What To Look For From SUPN

Supernus Pharmaceuticals is set to report its Q2 earnings this Tuesday after market hours. Analysts expect the company's revenue to grow by 24.3% year-on-year, improving from the previous year's 5.6% increase. Despite Supernus Pharmaceuticals beating revenue expectations last quarter, it significantly missed EPS estimates, …

Supernus and Indivior to Merge, Forming a New CNS-Focused Pharma Company

Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in an all-stock deal to form Supernus, Inc., a new CNS-focused pharmaceutical company. The combined entity will have a portfolio of 11 commercialized products across addiction, ADHD, depression, and Parkinson's disease, with nearly $2.2 billion in revenue. …

CNS-focused Supernus and Indivior agree merger terms

Supernus Pharma and Indivior have agreed to an all-stock merger, forming a new company, Supernus Inc., focused on CNS diseases with combined revenues of around $2.2 billion. The deal, expected to close in Q4, will see Indivior shareholders owning 56.5% of the new company …

Rockville's Supernus more than tripling size through merger of equals

Rockville's Supernus Pharmaceuticals is merging with Richmond-based Indivior in a "merger of equals" transaction. The combined company will be led by current Supernus CEO Jack Khattar and is expected to generate approximately $2.2 billion in annual revenue from nearly a dozen neurological and psychiatric …

Supernus Q2 Falls To Loss, Despite 32% Revenue Jump; To Merge With Indivior In All-Stock Deal

(RTTNews) - Supernus Pharmaceuticals Inc. (SUPN) Monday reported a slip to loss in the second quarter, on one-time impairment charges, interest expense and a reversal of income tax benefit to an expense, despite a 32% increase in revenue, compared to the prior year. The …

Shareholder Alert: Ademi LLP investigates whether Supernus Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders

Ademi LLP is investigating Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) for potential breaches of fiduciary duty related to its transaction with Indivior Pharmaceuticals. Supernus shareholders are set to receive 1.5401 common shares of Indivior for each Supernus share, resulting in Supernus stockholders owning approximately 43.5% …

Compared to Estimates, Supernus (SUPN) Q2 Earnings: A Look at Key Metrics

Supernus Pharmaceuticals (SUPN) reported $219.06 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 32.4%. EPS of $0.54 for the same period compares to $0.91 a year ago. The reported revenue represents a surprise of +6.84% over the Zacks …

Supernus jumps premarket on merger deal; GameStop drops

Investing.com - U.S. stock index futures advanced on Monday after President Donald Trump said negotiations with Iran were set to begin this week, easing geopolitical concerns that had rattled markets in recent weeks, while technology stocks attempted to extend their recovery following July's sharp …

At a glance: stocks gapping up premarket

[Wall Street New York City] aluxum/E+ via Getty Images Here's a quick look at the stocks that are seeing gap-up moves before the bell on Monday. Stock index futures were higher on Monday as investors looked forward to a busy week of corporate earnings …

Supernus Pharmaceuticals Reports 32% Second-Quarter 2026 Revenue Growth, Raises Full-Year Guidance and Announces Merger with Indivior

Supernus Announces Second Quarter 2026 Financial Results

Supernus Pharmaceuticals, Inc. Total revenues were $219.1 million in the second quarter 2026, a 32% increase compared to same period last year. Combined revenues of the Company's four growth products increased to $175.7 million in the second quarter 2026, representing an increase of 52% …

Supernus, Indivior merge to beef up brain drug portfolio

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: Brain drug developers Supernus and Indivior on Monday announced plans to merge, bringing together two companies specializing in drugs for …

Supernus Pharmaceuticals Reports 32% Second-Quarter 2026 Revenue Growth, Raises Full-Year Guidance and Announces Merger with Indivior | SUPN Stock News